25Madison Ventures Fund II, L.P. has announced a significant move in the private investment landscape by filing a new Form D with the SEC. This filing indicates the company is launching a venture capital fund offering with a total amount of $50 million. This development is important as it reflects the company's strategy to attract accredited investors and capitalize on potential growth opportunities in the market.
Background
25Madison Ventures Fund II, L.P. is a limited partnership based in New York, incorporated in Delaware. The company focuses on pooled investment funds, specifically in the venture capital sector. The recent filing, dated October 30, 2026, is part of their ongoing efforts to raise capital for investment. The company is represented by Steven Price, who serves as the Managing Member of the General Partner.
What the Filing Says
The filing states that the company is offering a total of $50 million, with no amounts sold yet. It highlights that the offering is not expected to exceed one year and is aimed at accredited investors only. The document notes, "Rule 506(b) provides a 'safer harbor' for a private offering," indicating the legal framework under which this offering is being made.
Impact
This offering may affect various stakeholders, including potential investors looking for opportunities in the venture capital space. The focus on accredited investors suggests that 25Madison Ventures Fund II, L.P. is targeting a specific market segment, which could impact competition among other venture capital firms. The filing indicates that the company is not currently accepting investments from non-accredited investors.
What's Next
The filing does not say what happens next, but it sets the stage for future updates as the company seeks to attract investors for its new fund.
Read Next
BP Sells 5% Stake in Aker BP for $1.06 Billion
WeRide Inc. Reports Stability in Share Capital Movements
Bullish Releases October 2026 Monthly Metrics Report
Chimera Investment Corp declares cash dividends for Q4 2026
Modern Mining Technology registers common shares on NYSE American
Innate Pharma Reports Q3 2026 Update, Highlights Pipeline Progress










